Pfizer pivots from early-stage rare disease R&D
Moderna caps off busy week with $1.2B CytomX collab to better target mRNA therapies
UK signs deal with BioNTech for cutting-edge cancer trials
J&J's consumer health unit Kenvue files for official separation
*please scroll down for all the latest news*
